Developing Peer and Patient Education Materials “Teaching is a skill and a gift, a talent and a technique.� Heimlich and Norland, 1994
Mary Lynn McPherson, Pharm.D., BCPS Professor and Vice Chair for Education University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu 1
Disclosure • Nothing to Disclose
Learning Objectives • At the conclusion of this session, the PainWeek attendee will be able to: – Describe all eight elements of a Design Plan with 100% accuracy. – Describe all nine events of instruction that comprise a Lesson Plan with 100% accuracy. – Given a topic and supporting materials, prepare a Design Plan and Lesson Plan that includes all elements.
Design Plan A detailed explanation of the educational project
• • • •
Rationale Target population Description Objectives
• • • •
Evaluation Strategy Participant Prerequisites Facilitator Prerequisites Deliverables
Opioid-Induced Hyperalgesia
Rationale • Opioids are commonly used to treat pain • Practitioners know most common adverse effects of opioids • Many practitioners are unfamiliar with opioidinduced hyperalgesia (OIH) • Survey of hospice medical directors showed only moderate confidence in staff physicians; low confidence in non-hospice physicians at identifying and managing OIH
Target Population Course Description • Target population – Staff hospice physicians – Referring physicians
• Course description – 2 hour session on recognition and management of OIH – Facilitated by hospice Medical Director
Course Objectives • Upon conclusion of this learning activity, the participant will be able to:
– Given an actual or simulated opioid-tolerant pain patient, differentiate between opioid-induced hyperalgesia and five other clinical scenarios that may warrant an opioid dose increase, based on two aspects of pain presentation and response to therapy. – Given an actual or simulated opioid-tolerant pain patient with suspected opioid-induced hyperalgesia, calculate an equianalgesic dosage regimen of methadone, including total daily dose, dosing frequency and timing of dosage conversion. – Given an actual or simulated opioid-tolerant pain patient with suspected opioid-induced hyperalgesia, write an order for ketamine, including starting dose, dosing frequency, and titration schedule. 8
Evaluation Strategies Objective
Evaluation Strategy
1a. The physician will be able to differentiate between worsening pain pathology, opioid tolerance, opioid withdrawal, opioid addictive disease, pseudoaddiction and opioid-induced analgesic based on pain presentation, specifically quality of pain complaint, and region or radiation of pain complaint. 1b. The physician will be able to differentiate between worsening pain pathology, opioid tolerance, opioid withdrawal, opioid addictive disease, pseudoaddiction and opioid-induced analgesic based on temporal aspect of pain presentation (e.g., gradual vs. abrupt, or variable).
Peer and facilitator observation, and Level 2 evaluation
1c. The physician will be able to differentiate between worsening pain pathology, opioid tolerance, opioid withdrawal, opioid addictive disease, pseudoaddiction and opioid-induced analgesic based on response to opioid increase (e.g., pain improves or worsens).
Peer and facilitator observation, and Level 2 evaluation
2a. The physician will be able to calculate the patient’s total daily dose of opioid including scheduled doses and average use of “as needed� doses. 2b. The physician will be able to determine the appropriate morphine : methadone ratio (e.g., 10:1 or 20:1) given patients age, total daily oral morphine dose equivalent and potential drug interactions. 2c. The physician will be able to calculate the oral methadone dosage regimen including milligram dose, dosage formulation (e.g., tablet or oral solution strength), dosing interval, and time to start relative to last dose of previous opioid. 3a. The physician will be able to order a starting dose of ketamine for both oral and parenteral administration.
Peer and facilitator observation
3b. The physician will be able to increase ketamine including the frequency of increase, and magnitude of dosage increase. 3c. The physician will be able to list three ketamine-induced dose-limiting adverse effects.
Peer and facilitator observation,
Peer and facilitator observation, and Level 2 evaluation
Peer and facilitator observation
Peer and facilitator observation, and Level 2 evaluation Peer and facilitator observation, and Level 2 evaluation
Level 2 evaluation
Prerequisites • Participants – Hospice staff physicians – Non-hospice physicians who refer to hospice
• Facilitator – Hospice Medical Director – Completed “Train-the-Trainer” education
Deliverables Design plan Lesson plan Draft of all materials PowerPoint presentation with notes for facilitators • Participant handouts • • • •
– Think-Pair-Share Worksheets – PowerPoint slide handout – Methadone and ketamine protocols
• Levels 1 and 2 evaluations
Lesson Plan 9 Events of Instruction • Preparation for learning – Gaining attention – Direction – Recall
• Delivery and Practice of New Material – – – –
Content Application feedback – level 1 Application feedback – level 2 Application feedback – level 3
• Wrap-Up
– Evaluation – Closure
Opioid-Induced Hyperalgesia: Seriously, I’m making things WORSE? Name of speaker Affiliation
13
Gaining Attention (10 minutes)
Meet Mr. P. • 48 year old Caucasian male with an admitting hospice diagnosis of sepsis • Patient quadriplegic. • History of MI, CVA, PEG placement and removal, seizures, extensor tone spasms (that bent cervical titanium rod in cervical spine), chronic neuropathic pain, sacral wound • Recently elected comfort care only (no further admissions) 15
Mrs. P. says… • She is very worried about new plan of care because the patient has “excruciating pain when he becomes septic…he screams until he becomes hoarse from the pain.” • She has experienced this for the past 5 years. • Patient a complete assist for all ADLs. • Patient 72”, weight 170 lbs, BMI 23 • PPS 20% 16
Analgesics for Mr. P. on Admission • Implanted pump delivering baclofen (“stateallowed maximum dose”) • Transdermal fentanyl 150 mcg/hour • Transitioned from oral morphine 750 mg per day to hydromorphone 8 mg/hour continuous IV infusion (RN then called pharmacist) • Patient hypervigilant, spasming, screaming in pain, says it hurts EVERYWHERE • What to do? 17
Direction (5 minutes)
Upon conclusion of this learning activity, the participant will be able to: • Given an actual or simulated opioid-tolerant pain patient, differentiate between opioid-induced hyperalgesia and five other clinical scenarios that may warrant an opioid dose increase, based on two aspects of pain presentation and response to therapy. • Given an actual or simulated opioid-tolerant pain patient with suspected opioid-induced hyperalgesia, calculate an equianalgesic dosage regimen of methadone, including total daily dose, dosing frequency and timing of dosage conversion. • Given an actual or simulated opioid-tolerant pain patient with suspected opioid-induced hyperalgesia, write an order for ketamine, including starting dose, dosing frequency, and titration schedule. 19
Recall (10 minutes)
Opioid Therapy • Cornerstone of therapy for the treatment of moderate to severe pain (cancer, non-cancer) • Increased availability and comfort level in using opioids in recent years – Greater attention to pain management – Better education – Used earlier in disease process – Used in higher doses
21
Adverse Effects of Opioids • • • •
Nausea, vomiting Constipation Pruritus Sleepy
22
What’s going on? • A common clinical observation:
Progression
Clin J Pain 2008;24:479-496
Opioid Tolerance
Opioid-Induced Pain
Disease
Opioid Tolerance
Disease Progression
– Opioid-requiring patients need a dosage increase to maintain adequate analgesia. Why? OpioidInduced Pain (OIH)
23
Content (15 minutes)
CNS Adverse Effects of Opioids • Adverse effects of opioids on CNS (neurotoxicity - damage to nerve cells) – Reduced level of consciousness (sedation, drowsiness, sleep disturbance) – Adverse effects on thinking process and ability to reaction (cognitive impairment, psychomotor impairment, delirium, hallucinations, dreams, nightmares) – Direct toxic effect on neurons (myoclonus, seizures, hyperalgesia and tolerance) 25
OIH and Opioid Tolerance
26
OIH vs. Tolerance
Clin J Pain 2008;24:479-496; A – OIH; B - Tolerance
27
Vicious Cycle of Opioid-Induced Neurotoxicity
http://palliative.info/pages/TeachingMaterial.htm
28
Application 1 (10 minutes)
Exercise 1 • ES is a 72 year old man admitted to hospice with end-stage colon cancer, widely metastatic. • On admission to hospice he was receiving long-acting oral morphine 60 mg by mouth every 12 hours. His pain was primarily in his abdomen, and he rated it as a 6 on average, a worst of 8 and a best of 4. • Over the month after admission, his pain increased (8 on average, worst of 10, best of 6-7) and his morphine was increased to 120 mg by mouth every 12 hours, with oral morphine solution 30 mg every 2 hours as needed (using about 6 doses per day). • He now states the pain has extended well beyond his abdomen, in fact “it hurts pretty much everywhere.” He complains that his pajamas and even the bed sheets are painful to his skin. • Complete Exercise 1.
30
When opioids don’t get the job done Condition
Nature of pain
Presentation of onset of pain
Response to Opioid Admin
Worsening pain pathology
Localized to site of pre-existing pain or new site of pathology
Variable, depending on source of pain
Pain improves
Opioid tolerance
Localized to site of pre-existing pain
Gradual onset
Pain improves
Opioid withdrawal
Increased sensitivity to pain; diffuse, may extend beyond distribution of pre-existing pain
Abrupt with SA opioids or antagonist administration; gradual with LA opioids
Pain improves
Opioid addictive disease
Increased sensitivity to pain; diffuse, may extend beyond distribution of pre-existing pain
Gradual onset
Pain may improve, but function may worsen
Pseudoaddiction
Localized to site of pre-existing pain; pain is undertreated, causing patient to seek opioids (may be mistaken for addiction)
Variable, depending on source of pain
Pain improves
Opioidinduced hyperalgesia
Pain abnormal in presentation (often with allodynia); increased sensitivity to pain; diffuse, may extend beyond distribution of pre-existing pain or be widespread (panalgesia); may be associated with delirium, agitation, seizures, myoclonus
Abrupt onset with rapid opioid escalation or high-dose opioid administration
Pain worsens
J PeriAnesthesia Nursing 2012;27(1):46-50; Br J Clin Pharm 2010;2:153-156
31
Content (continued) (25 minutes)
Br J Clin Pharm 2010;2:153-156.
33
Morphine and Hydromorphone
Active Metabolite Accumulation in Renal Failure
http://palliative.info/pages/TeachingMaterial.htm
34
Analgesics for Mr. P. on Admission • Implanted pump delivering baclofen (“stateallowed maximum dose”) • Transdermal fentanyl 150 mcg/hour • Transitioned from oral morphine 750 mg per day to hydromorphone 8 mg/hour continuous IV infusion (RN called pharmacist) • Patient hypervigilant, spasming, screaming in pain, says it hurts EVERYWHERE • What to do? 35
Management of OIH • Hydration if clinically appropriate • Reduce the opioid dose – Consider use of an opioid-sparing coanalgesic • Acetaminophen, NSAID
• Opioid rotation – Allows comparable analgesia at a lower equianalgesic dose – Fentanyl – Methadone • NMDA receptor antagonist
• Ketamine (NMDA receptor antagonist) 36
Methadone
(refer to Methadone Protocol) • Potential candidates / inappropriate candidates • Assessing co-morbidities / cardiovascular risk • Calculate total daily dose / convert to oral morphine • 10:1 or 20:1; adjust for interacting drugs • Selecting the methadone dose • Implementing therapy • Monitoring response; adjusting therapy • Educating patients, families, caregivers 37
Application 2 (10 minutes)
Exercise 2 – Mr. P. • Implanted pump delivering baclofen (“state maximum dose”) • Transdermal fentanyl 150 mcg/hour • Hydromorphone 8 mg/hour continuous IV infusion (call to pharmacist) • How would you convert Mr. P. to oral methadone? See Exercise 2. • Patient is receiving no other medications. 39
Exercise 2 – Mr. P. • Transdermal fentanyl 150 mcg/hour – 300 mg oral morphine per day
• Hydromorphone 8 mg/hour continuous IV infusion – 8 mg/hour x 24 hours = 192 mg IV HM per day – 192 mg x 20 = 3840 mg oral morphine per day
• TDD oral morphine = 4140 mg • Use a 40:1 (oral morphine : methadone conversion) → 103.5 mg oral methadone per day – No interacting drugs – Methadone 30 mg po q8h – Oral morphine solution 60-100 mg hourly as needed • Or could keep IV hydromorphone for prn dosing
40
Content (continued) (10 minutes)
Ketamine (refer to Ketamine Protocol) • • • •
Mechanism of action – NMDA antagonist Indications for use / contraindications Adverse effects Dosage and administration – IV, SQ, continuous infusion – Oral, topical
• Monitoring and response to therapy 42
Application 3 (10 minutes)
Exercise 3 – Ms. R. • Ms. R. is a 43 year old woman with end-stage cervical cancer. She is admitted to hospice from the hospital, on IV morphine 80 mg/hour with a 20 mg bolus every 15 minutes (uses about once an hour). • She is experiencing myoclonus, and the hospice medical director prescribed lorazepam 2 mg po q6h scheduled. • Two days after admission the patient went on vacation for a week to the ocean. 44
Exercise 3 – Ms. R. • When the patient returned from vacation, she was admitted directly back to the hospital. It was discovered that she spent most of her ocean side vacation in the local hospital complaining of increased pain and myoclonus. • On returning home, she is now on IV morphine 130 mg/hour plus a 30 mg bolus, which she uses once or twice an hour, plus a continuous infusion of midazolam at 10 mg/hour. She continues to experiences significant myoclonus. • Patient has a history of a prolonged QTc and refuses methadone therapy. • Determine a plan that incorporate ketamine to treat Ms. R.
45
Exercise 3 – Ms. R. • Begin ketamine 10 mg po q6h, mixed in orange juice • Empirically reduce morphine infusion by 30% to 90 mg/hour; keep bolus in place • Empirically reduce midazolam infusion by 50% to 5 mg/hour • Increase ketamine by 10 mg per dose every 23 days (while titrating morphine and midazolam down) 46
Wrap-Up/Evaluation (10 minutes)
Clinical Guidelines for the Use of Chronic Opioid Therapy in Chronic Noncancer Pain (APS/AAPM) • “Management of treatment-refractory patients on high doses of COT is challenging.” – Substance abuse, diversion – Increased adverse effects
• “Hyperalgesia, neuroendocrinologic dysfunction and possibly immunosuppression may be more likely at higher opioid doses…[> 200 mg oral morphine TDD]” – Opioid treatment may be require restructuring J Pain 2009;10:113-130; COT – chronic opioid therapy; TDD – total daily dose
48
Clinical Features OIH History • Increasing sensitivity to pain stimuli (hyperalgesia) • Worsening pain despite increasing doses of opioids • Pain that becomes more diffuse, extending beyond the distribution of pre-existing pain • Can occur at any dose of opioid, but more commonly with high parenteral doses of morphine or hydromorphone and/or in the setting of renal impairment/failure. Fast Facts and Concepts #142: Opioid-Induced Hyperalgesia
49
Clinical Features OIH Physical Examination • Pain elicited from ordinarily non-painful stimuli such as stroking skin with cotton (allodynia) • Presence of other opioid hyperexcitability effects – Myoclonus, delirium, seizures
Fast Facts and Concepts #142: Opioid-Induced Hyperalgesia
50
Clinical Features OIH Proposed Mechanisms • Toxic effect of opioid metabolites (e.g., morphine3-glucuronide or hydromorphone-3-glucuronide) • Central sensitization as a result of opioid-related activation of N-methyl-D-aspartate (NMDA) receptors in the central nervous system • Increase in spinal dynorphin activity • Enhanced descending facilitation from the rostral ventromedial medulla • Activation of intracellular protein kinase C Fast Facts and Concepts #142: Opioid-Induced Hyperalgesia
51
Clinical Features OIH Therapies • Reduce or discontinue the current opioid • Change opioid to one with less risk of neurotoxic effects: fentanyl or methadone • Add an infusion of a non-opioid NMDA receptor antagonist such as ketamine • Add a non-opioid adjuvant such as acetaminophen or NSAID • Initiate epidural, intrathecal, regional or local anesthesia and taper/discontinue systemic opioids • Increase hydration if clinically appropriate Fast Facts and Concepts #142: Opioid-Induced Hyperalgesia
52
Closure (5 minutes)
What are the three most important things you learned today?
54
Evaluation (Level 1)
Evaluation (Level 2)
Opioid-Induced Hyperalgesia: Seriously, I’m making things WORSE? Seasons Hospice & Palliative Care
57
Developing Peer and Patient Education Materials “Teaching is a skill and a gift, a talent and a technique.� Heimlich and Norland, 1994
Mary Lynn McPherson, Pharm.D., BCPS Professor and Vice Chair for Education University of Maryland School of Pharmacy mmcphers@rx.umaryland.edu 58